FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207245637> ?p ?o ?g. }

• W3207245637 endingPage "317" @default.
• W3207245637 startingPage "308" @default.
• W3207245637 abstract "Abstract Purpose: The role of immunotherapy in hormone receptor (HR)-positive, HER2-negative breast cancer is underexplored. Patients and Methods: The neoadjuvant phase II GIADA trial (NCT04659551, EUDRACT 2016-004665-10) enrolled stage II–IIIA premenopausal patients with Luminal B (LumB)-like breast cancer (HR-positive/HER2-negative, Ki67 ≥ 20%, and/or histologic grade 3). Patients received: three 21-day cycles of epirubicin/cyclophosphamide followed by eight 14-day cycles of nivolumab, triptorelin started concomitantly to chemotherapy, and exemestane started concomitantly to nivolumab. Primary endpoint was pathologic complete response (pCR; ypT0/is, ypN0). Results: A pCR was achieved by 7/43 patients [16.3%; 95% confidence interval (CI), 7.4–34.9]; the rate of residual cancer burden class 0–I was 25.6%. pCR rate was significantly higher for patients with PAM50 Basal breast cancer (4/8, 50%) as compared with other subtypes (LumA 9.1%; LumB 8.3%; P = 0.017). Tumor-infiltrating lymphocytes (TIL), immune-related gene-expression signatures, and specific immune cell subpopulations by multiplex immunofluorescence were significantly associated with pCR. A combined score of Basal subtype and TILs had an AUC of 0.95 (95% CI, 0.89–1.00) for pCR prediction. According to multiplex immunofluorescence, a switch to a more immune-activated tumor microenvironment occurred following exposure to anthracyclines. Most common grade ≥3 treatment-related adverse events (AE) during nivolumab were γ-glutamyltransferase (16.7%), alanine aminotransferase (16.7%), and aspartate aminotransferase (9.5%) increase. Most common immune-related AEs were endocrinopathies (all grades 1–2; including adrenal insufficiency, n = 1). Conclusions: Luminal B-like breast cancers with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti–PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context." @default.
• W3207245637 created "2021-10-25" @default.
• W3207245637 creator A5010742357 @default.
• W3207245637 creator A5020747800 @default.
• W3207245637 creator A5023036757 @default.
• W3207245637 creator A5024264121 @default.
• W3207245637 creator A5028177740 @default.
• W3207245637 creator A5034632931 @default.
• W3207245637 creator A5035108656 @default.
• W3207245637 creator A5043632549 @default.
• W3207245637 creator A5048767543 @default.
• W3207245637 creator A5048969389 @default.
• W3207245637 creator A5051550047 @default.
• W3207245637 creator A5055333835 @default.
• W3207245637 creator A5058093044 @default.
• W3207245637 creator A5063676677 @default.
• W3207245637 creator A5068486162 @default.
• W3207245637 creator A5068906915 @default.
• W3207245637 creator A5085165482 @default.
• W3207245637 creator A5091866109 @default.
• W3207245637 date "2021-10-19" @default.
• W3207245637 modified "2023-10-09" @default.
• W3207245637 title "Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial" @default.
• W3207245637 cites W2029445248 @default.
• W3207245637 cites W2075894019 @default.
• W3207245637 cites W2093424661 @default.
• W3207245637 cites W2100141308 @default.
• W3207245637 cites W2119549339 @default.
• W3207245637 cites W2120431466 @default.
• W3207245637 cites W2128458647 @default.
• W3207245637 cites W2132619562 @default.
• W3207245637 cites W2147415463 @default.
• W3207245637 cites W2208824773 @default.
• W3207245637 cites W2321044145 @default.
• W3207245637 cites W2504940557 @default.
• W3207245637 cites W2585697071 @default.
• W3207245637 cites W2771978163 @default.
• W3207245637 cites W2784030537 @default.
• W3207245637 cites W2801511839 @default.
• W3207245637 cites W2806866264 @default.
• W3207245637 cites W2897147983 @default.
• W3207245637 cites W2944687997 @default.
• W3207245637 cites W2968651230 @default.
• W3207245637 cites W2982542437 @default.
• W3207245637 cites W2990398119 @default.
• W3207245637 cites W2994903788 @default.
• W3207245637 cites W3005738019 @default.
• W3207245637 cites W3006930853 @default.
• W3207245637 cites W3012919887 @default.
• W3207245637 cites W3039669945 @default.
• W3207245637 cites W3087393791 @default.
• W3207245637 cites W3121062648 @default.
• W3207245637 cites W3172174831 @default.
• W3207245637 cites W4200350191 @default.
• W3207245637 cites W4211123279 @default.
• W3207245637 doi "https://doi.org/10.1158/1078-0432.ccr-21-2260" @default.
• W3207245637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34667023" @default.
• W3207245637 hasPublicationYear "2021" @default.
• W3207245637 type Work @default.
• W3207245637 sameAs 3207245637 @default.
• W3207245637 citedByCount "29" @default.
• W3207245637 countsByYear W32072456372020 @default.
• W3207245637 countsByYear W32072456372021 @default.
• W3207245637 countsByYear W32072456372022 @default.
• W3207245637 countsByYear W32072456372023 @default.
• W3207245637 crossrefType "journal-article" @default.
• W3207245637 hasAuthorship W3207245637A5010742357 @default.
• W3207245637 hasAuthorship W3207245637A5020747800 @default.
• W3207245637 hasAuthorship W3207245637A5023036757 @default.
• W3207245637 hasAuthorship W3207245637A5024264121 @default.
• W3207245637 hasAuthorship W3207245637A5028177740 @default.
• W3207245637 hasAuthorship W3207245637A5034632931 @default.
• W3207245637 hasAuthorship W3207245637A5035108656 @default.
• W3207245637 hasAuthorship W3207245637A5043632549 @default.
• W3207245637 hasAuthorship W3207245637A5048767543 @default.
• W3207245637 hasAuthorship W3207245637A5048969389 @default.
• W3207245637 hasAuthorship W3207245637A5051550047 @default.
• W3207245637 hasAuthorship W3207245637A5055333835 @default.
• W3207245637 hasAuthorship W3207245637A5058093044 @default.
• W3207245637 hasAuthorship W3207245637A5063676677 @default.
• W3207245637 hasAuthorship W3207245637A5068486162 @default.
• W3207245637 hasAuthorship W3207245637A5068906915 @default.
• W3207245637 hasAuthorship W3207245637A5085165482 @default.
• W3207245637 hasAuthorship W3207245637A5091866109 @default.
• W3207245637 hasBestOaLocation W32072456371 @default.
• W3207245637 hasConcept C121608353 @default.
• W3207245637 hasConcept C126322002 @default.
• W3207245637 hasConcept C143998085 @default.
• W3207245637 hasConcept C2776694085 @default.
• W3207245637 hasConcept C2776755627 @default.
• W3207245637 hasConcept C2777701055 @default.
• W3207245637 hasConcept C2780030458 @default.
• W3207245637 hasConcept C2780835546 @default.
• W3207245637 hasConcept C2781190966 @default.
• W3207245637 hasConcept C530470458 @default.
• W3207245637 hasConcept C71924100 @default.
• W3207245637 hasConcept C90924648 @default.
• W3207245637 hasConceptScore W3207245637C121608353 @default.

• next